101-26-8
101-26-8
Chemical Structure
Pyridostigmine bromide
- CAS No.: 101-26-8
- Formula:C9H13BrN2O2
- Molecular Weight:261.12
IUPAC Name: 3-((dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium bromide
InChIKey: VNYBTNPBYXSMOO-UHFFFAOYSA-M
SMILES: C[N+]1=CC=CC(OC(N(C)C)=O)=C1.[Br-]
Biological Activity: Pyridostigmine bromide is an orally active cholinesterase (ChE) inhibitor that can be used in cardiovascular disease research[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pyridostigmine bromide | 98.86% | Pyridostigmine bromide is an orally active cholinesterase (ChE) inhibitor that can be used in cardiovascular disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pyridostigmine bromide (Standard) | ≥98% | Pyridostigmine (bromide) (Standard) is the analytical standard of Pyridostigmine (bromide). This product is intended for research and analytical applications. Pyridostigmine bromide is a reversible cholinesterase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pyridostigmine-d6 bromide | 99.86% | Pyridostigmine-d6 (bromide) is the deuterium labeled Pyridostigmine, which is a parasympathomimetic and a reversible cholinesterase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pyridostigmine-d3 bromide | Pyridostigmine-d3 (bromide) is the deuterium labeled Pyridostigmine bromide. Pyridostigmine bromide is a parasympathomimetic and a reversible cholinesterase inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gales BJ, et al. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8. Epub 2007 Feb 6. [Content Brief]
- [2]. Kanjwal K, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011 Jun;34(6):750-5. [Content Brief]
- [3]. Bernatova I, et al. Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice[J]. Pharmacology Biochemistry and Behavior, 2003, 74(4): 901-907. [Content Brief]
- [4]. de Cuba MB, et al. Effects of cholinergic stimulation with pyridostigmine bromide on chronic chagasic cardiomyopathic mice. Mediators Inflamm. 2014;2014:475946. [Content Brief]
- [5]. Azzolin VF, et al. Effects of Pyridostigmine bromide on SH-SY5Y cells: An in vitro neuroblastoma neurotoxicity model. Mutat Res Genet Toxicol Environ Mutagen. 2017 Nov;823:1-10. [Content Brief]
